Skip to main content
GlaxoSmithKline PLC logo

GlaxoSmithKline PLC — Investor Relations & Filings

Ticker · GSK ISIN · GB00BN7SWP63 LEI · 5493000HZTVUYLO1D793 IL Manufacturing
Open in API
Filings indexed 7,016 across all filing types
Latest filing 2026-02-11 Director's Dealing
Country GB United Kingdom
Listing IL GSK

About GlaxoSmithKline PLC

https://www.gsk.com/en-gb/

GSK plc is a global biopharmaceutical company that unites science, technology, and talent to research, develop, and manufacture medicines and vaccines. The company focuses on preventing and treating disease across four primary therapeutic areas: infectious diseases, HIV, oncology, and immunology/respiratory. Its portfolio consists of specialty medicines and vaccines aimed at addressing significant global health needs. GSK's strategy centers on leveraging its research and development capabilities to deliver new health solutions.

Recent filings

Filing Released Lang Actions
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is a notification of transactions involving Persons Discharging Managerial Responsibilities (PDMRs) related to the vesting of Deferred Annual Bonus Plan awards and subsequent sales of shares to meet tax liabilities. It details specific transactions of share vesting and sales by named executives, including dates, prices, volumes, and transaction venues. There is no indication of financial statements, earnings data, management discussion, or report publication. The document is a regulatory disclosure of insider dealings by directors and senior management, consistent with insider trading or director dealing notifications. Therefore, the document fits the category of Director's Dealing (DIRS). The document length and detail support a confident classification.
2026-02-11 English
6-K Filing
Regulatory Filings
2026-02-11 English
6-K Filing
Regulatory Filings
2026-02-11 English
6-K Filing
Regulatory Filings
2026-02-11 English
6-K Filing
Regulatory Filings
2026-02-11 English
China CDE accepts Arexvy adults 60+ application
Regulatory Filings Classification · 98% confidence The document is a press release issued via the Regulatory News Service (RNS) by GSK PLC. It announces that their RSV vaccine, Arexvy, has been accepted for regulatory review in China. This is a corporate announcement regarding product development and regulatory status, which falls under the 'Regulatory Filings' category as it does not fit into specific financial reporting or governance categories.
2026-02-10 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.